Argent Biopharma (ASX:RGT) Shares Rise: What Investors Should Know

Sonal Goyal

13 November 2026 01:18 PM AEDT

Argent Biopharma (ASX:RGT) Shares Rise: What Investors Should Know

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Argent Biopharma shares were trading at $0.021 during the 13 November 2026 session, up 10.53%.
The company has refocused on immune modulation and inflammatory disease following the global licensing of CannEpil.
An exclusive, royalty-bearing licence covering NLC antiviral applications was signed during the quarter.

During the Trading session on 13 November 2026, Argent Biopharma Ltd (ASX:RGT) shares were trading at $0.021, up 10.53%, while the S&P/ASX 200 was down 0.73% at 9,079.70 at 12:39 pm AEDT. Argent is a Drug Development company with a portfolio that includes CimetrA, ArtemiC and CannEpil. Its latest update was its September 2026 quarterly activity report and cash flow statement, released on 23 October 2026.

Refined strategic focus

After quarter end, the company refined its strategy to concentrate resources on immune modulation and inflammatory disease, following the global licensing of CannEpil. Its key elements include RGT-CA91980 as the lead internally developed program, building on the CimetrA and ArtemiC development history. Argent also holds commercial rights to the NLC platform and a preclinical NanoBodies program. The company said it does not present CimetrA as an anti-ageing medicine.

NLC antiviral licence

During the quarter, Argent entered a licence agreement with NLC Ltd, NLC Viral Defense and Dr Dorit Arad. The agreement grants an exclusive, royalty-bearing licence to commercialise the antiviral applications of NLC's Tollovir, excluding the NLCV-001 clinical trial formulation, as well as Tollovid and NutraVir products and related formulations. Argent said the licence expands its antiviral portfolio alongside CimetrA.

Priorities and Capital Markets position

Argent listed its priorities as commercialisation and Revenue generation through CimetrA and the NLC portfolio, CannEpil licensing, Manufacturing and regulatory support, and research into inflammaging and healthy ageing. The company also said it is strengthening its corporate and capital markets positioning, including a U.S. capital markets strategy.

Sector context

Early-stage drug developers in Australia often rely on licensing deals and partnerships to generate income before commercial products reach the market. Development in immune and inflammatory disease areas is competitive and requires regulatory approvals that can take years. Companies with small capital bases typically rely on Equity raisings and licensing income to fund programs.

Risks investors are watching

Commercial revenue from CimetrA, the NLC portfolio and CannEpil licensing has yet to be established at a scale that funds the business, and the timing of any Royalty income is uncertain. Drug development carries clinical, regulatory and funding risks, and the NanoBodies program is preclinical. The company's strategy also covers several areas, so resource allocation may be a consideration for investors.

What to watch ahead

Investors will look for progress on commercialisation of CimetrA and the NLC products, updates on the lead RGT-CA91980 program, and the next quarterly cash flow report. Details of any U.S. capital markets activity and the outcomes of regulatory support for CannEpil will also be followed.

Final Word

Argent's latest quarterly update shows a narrower strategic focus alongside an expanded antiviral licence. The next reports will show how these commercial and development priorities progress.

FAQs

Q: What did Argent Biopharma announce regarding its strategy?

A: The company refined its strategy to focus on immune modulation and inflammatory disease following the global licensing of CannEpil.

Q: What licence did Argent sign during the quarter?

A: It signed an exclusive, royalty-bearing licence to commercialise the antiviral applications of NLC's Tollovir, Tollovid and NutraVir products, among others.

Q: What is Argent's lead internally developed program?

A: The company named RGT-CA91980 as its lead internally developed program.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.